ArticleEJNMMI radiopharmacy and chemistry2025
Aluminum-[
Article in EJNMMI radiopharmacy and chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Glycoengineering Enables Fluorine-18 Radiolabeling of T Lymphocytes via Dual-Bioorthogonal Chemistry.Bioconjugate chemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe development of safer and more effective cell-based therapies requires robust methods for tracking cells in vivo. Positron emission tomography (PET) is a highly sensitive nuclear imaging technique capable of quantitatively tracking the in vivo fate of cells after administration. Here, we investigated a cell-labeling strategy based on metabolic glycoengineering (MGE) to introduce azides on the cell surface, followed by radiolabeling via the bioorthogonal perfluoroaryl azide (PFAA)-Staudinger reaction. We studied the metabolic incorporation of a tetraacetylated PFAA-derivatized mannosamine in Jurkat cells and evaluated whether three triarylphosphines bearing the REstrained Complexing Agent (RESCA), could be radiolabeled with aluminum-[F]fluoride (Al[
resultsThree novel triarylphosphines containing different linkers (hydrophilic ester, ethylenediamine, and cyclohexyl) between the phosphine moiety and the (+)-RESCA-chelator were synthesized and characterized. Kinetic assays showed that all compounds reacted with the PFAA-derivatized monosaccharide, exhibiting different reaction kinetics under the tested conditions. They were successfully radiolabeled with fluorine-18 under optimized mild conditions and provided key insights into the radiolabeling of small molecules bearing the RESCA-chelator. The ester derivative underwent rapid chemical decomposition while the ethylenediamine- and cyclohexyl-linked derivatives were more resistant, with the cyclohexyl analogue showing the highest stability against demetallation and/or defluorination. However, radiolabeling with Al[
conclusionsWhile the Al[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.